In­cyte touts mid-stage da­ta for new JAK in­hibitor but stops short of se­lect­ing PhI­II dose

In­cyte is rolling out more mid-stage da­ta for its next-gen oral JAK in­hibitor, this time in an in­di­ca­tion where it’s re­cent­ly scored an ap­proval with an­oth­er drug.

Over the week­end at the 2023 Amer­i­can Acad­e­my of Der­ma­tol­ogy An­nu­al Meet­ing, the com­pa­ny spelled out re­sults from a Phase IIb tri­al of povorci­tinib among pa­tients with ex­ten­sive non­seg­men­tal vi­tili­go, a con­di­tion where peo­ple’s skin los­es col­or. In the study, the once-dai­ly pill helped more pa­tients than place­bo re­gain col­or on their skin, as mea­sured by a score of de­pig­men­ta­tion called T-VASI (to­tal Vi­tili­go Area Scor­ing In­dex).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER